Clindamycin 700mg iv q8h
ANTI-INFECTIVE DOSING RECOMMENDATIONS FOR RENAL q4h Clindamycin mg IV $ 14 mg q8h 42 Anti-infective_Dosing_Recommendations_for_Renal.
Indications and Usage for Clindamycin Capsules Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci.
Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate, clindamycin 700mg iv q8h. Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess typically resulting from anaerobic organisms resident in the normal gastrointestinal tract ; infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection.
Serious respiratory tract infections; serious skin and soft tissue infections. Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Clindamycin HCl and other antibacterial drugs, Clindamycin HCl should be used only to treat or prevent infections that are proven or strongly suspected to be caused by 700mg bacteria.
When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In q8h absence of such data, local epidemiology and susceptibility patterns may contribute clindamycin the empiric selection of therapy. Contraindications Clindamycin hydrochloride is contraindicated in individuals with a history of hypersensitivity to preparations containing clindamycin or lincomycin.
Clostridium difficile Associated Diarrhea Clostridium difficile associated diarrhea CDAD has been reported with use of nearly all antibacterial agents, including clindamycin HCl, and may range in severity from mild diarrhea to fatal colitis, clindamycin 700mg iv q8h. Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.
Hypertoxin producing strains of C. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful 700mg history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.
Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. In case of such an anaphylactic or severe hypersensitivity reaction, discontinue clindamycin permanently and institute appropriate therapy. A careful inquiry should be made concerning previous sensitivities to drugs and other allergens. Usage in Meningitis Since clindamycin does not diffuse adequately into the cerebrospinal fluid, the drug should not be used in the treatment of meningitis.
Precautions Q8h Review of experience to date suggests that a subgroup of older patients with associated severe illness may tolerate diarrhea less well.
When clindamycin clindamycin indicated in these patients, they should be carefully monitored for change in bowel frequency. Clindamycin hydrochloride should be prescribed with caution in individuals with a history of gastrointestinal disease, clindamycin 700mg iv q8h, particularly colitis. Clindamycin hydrochloride should be prescribed with caution in atopic individuals. Indicated surgical procedures should be performed in conjunction with antibiotic therapy, clindamycin 700mg iv q8h.
700mg use of clindamycin hydrochloride occasionally results in overgrowth of nonsusceptible organisms - particularly yeasts. Should superinfections occur, appropriate measures should be taken as indicated by the 700mg situation.
Clindamycin dosage modification may not be necessary in patients with renal disease. Clindamycin patients q8h moderate to severe liver disease, prolongation of clindamycin half-life has been found. However, it was postulated from studies that when given every q8h hours, accumulation should rarely occur.
Extra Drug Calculations and Answers June2013 (1)
Therefore, dosage modification in patients with clindamycin disease may not be necessary. However, periodic liver enzyme determinations should be made when treating patients with severe liver disease. Prescribing clindamycin HCl in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
Information for Patients Patients should be counseled that antibacterial drugs including clindamycin HCl should only be used to treat bacterial infections. They do not treat viral infections e. When clindamycin HCl is prescribed to treat a bacterial infection, clindamycin 700mg iv q8h, patients should be told that although it 700mg common q8h feel better early in the course 700mg therapy, the medication should be taken exactly 700mg directed.
Skipping doses q8h not completing the full course of therapy may 1 decrease the effectiveness of the immediate treatment and 2 increase the likelihood that bacteria will develop resistance and will not be treatable by clindamycin HCl or other antibacterial drugs in the future. Diarrhea is a common problem caused by antibiotics which clindamycin ends when the antibiotic is discontinued.
Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools with or without stomach cramps and fever q8h as late as two clindamycin more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible. Laboratory Tests During prolonged therapy, clindamycin 700mg iv q8h, periodic liver and kidney function tests and blood counts should be performed.
Drug Interactions Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents.
Therefore, it should be used with caution in patients receiving such agents. Clindamycin is metabolized predominantly by CYP3A4, and to a lesser extent clindamycin CYP3A5, to the major metabolite clindamycin sulfoxide and minor metabolite N desmethylclindamycin. Therefore inhibitors of CYP3A4 q8h CYP3A5 may increase plasma concentrations of clindamycin and inducers of these isoenzymes may reduce plasma concentrations of clindamycin.
In the presence of strong CYP3A4 inhibitors, monitor for adverse reactions. In the presence of q8h CYP3A4 inducers such as rifampicin, clindamycin 700mg iv q8h, monitor for loss of clindamycin. Antagonism has been demonstrated between clindamycin and erythromycin in vitro.
Q8h of possible clinical significance, these two drugs should not be administered concurrently, clindamycin 700mg iv q8h. Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term studies in animals have not been performed with clindamycin to evaluate carcinogenic potential. Genotoxicity tests performed included a rat micronucleus test and an Ames Salmonella reversion test. Both 700mg were negative. Pregnancy Teratogenic effects In clinical trials with pregnant women, the systemic administration of clindamycin during the second and third trimesters, has not been associated with an increased frequency of congenital abnormalities.
Clindamycin should be used during the 700mg trimester of pregnancy only if clearly needed. There are no adequate and well-controlled studies in pregnant women during the first trimester of pregnancy. Because animal reproduction studies are not always predictive of the human response, this drug should be used during pregnancy only if clearly needed.
Nursing Mothers Clindamycin has been reported to appear in 700mg milk in the range clindamycin 0.
Clindamycin has the potential to cause adverse effects on the breastfed infant's gastrointestinal flora. If oral or intravenous clindamycin is required by a nursing mother, it is not a reason to discontinue breastfeeding, but an alternate drug may be preferred. Monitor the infant for possible adverse effects on the gastrointestinal flora, such as diarrhea, candidiasis thrush, diaper rash or rarely, blood in the stool indicating possible antibiotic-associated colitis.
The developmental and health benefits q8h breastfeeding should be considered along with the mother's clinical need for clindamycin and any potential adverse effects on the breastfed child from clindamycin or from the underlying maternal condition.
Pediatric Use When clindamycin q8h is administered to the pediatric population birth to 16 yearsappropriate monitoring of organ system functions is desirable.
Geriatric Use Clinical studies of clindamycin did not include sufficient numbers of patients age 65 and over q8h determine whether they respond differently from younger 700mg. These patients should 700mg carefully monitored for the development of diarrhea.
Pharmacokinetic studies with 700mg have shown no clinically important differences between young and elderly subjects with normal hepatic function and normal age-adjusted renal function after oral or intravenous administration. Adverse Reactions The following reactions have been reported with the use of clindamycin. Esophageal ulcer has been reported. An unpleasant or metallic taste has been reported after oral administration.
Hypersensitivity Reactions Generalized mild to moderate morbilliform-like maculopapular skin rashes are the most frequently reported adverse reactions. Vesiculobullous rashes, as well as urticaria, clindamycin 700mg iv q8h, have been observed during drug therapy.
Cases of Acute Generalized Exanthematous Pustulosis AGEPclindamycin multiforme, some resembling Stevens-Johnson syndrome, anaphylactic shock, anaphylactic reaction and hypersensitivity have also been reported.
Clindamycin and Mucous Membranes Pruritus, vaginitis, angioedema and rare instances of exfoliative dermatitis have been reported. Liver Jaundice and clindamycin in liver function tests have been observed during clindamycin therapy, clindamycin 700mg iv q8h.
Cellulitis Empiric Therapy
Hematopoietic Transient neutropenia q8h and eosinophilia have clindamycin reported. Reports of agranulocytosis and thrombocytopenia have been made. No direct etiologic relationship to concurrent clindamycin therapy could be made in any of the foregoing. Musculoskeletal Cases of polyarthritis have been reported. 700mg the mice, convulsions and depression were observed.
Hemodialysis and peritoneal dialysis are not effective in removing clindamycin from the serum, clindamycin 700mg iv q8h. Adults Serious infections - to mg every 6 hours.
More severe infections - to mg every 6 hours. To avoid the possibility of esophageal irritation, clindamycin hydrochloride capsules, USP should be taken with a full glass of water. Clindamycin hydrochloride capsules are not suitable for children who nebenwirkungen candesartan 8mg unable to swallow them whole.
However, in clinically appropriate circumstances, the physician may elect to initiate treatment or continue treatment with clindamycin hydrochloride capsules, USP.
How is Clindamycin Capsules Supplied Clindamycin hydrochloride capsules, USP are available in the following strengths, colors and sizes: